FDA批准可注射微芯片神经调节装置治疗慢性疼痛

2014-12-09 高晓方 译 医学论坛网

FDA批准用于缓解慢性背痛和腿痛的可注射微芯片神经调节装置(SCS系统)上市。 SCS系统为微小的可注射微芯片装置,并可向神经周围的电极发送微能量脉冲,从而触发反应使大脑对特定疼痛信号从重新映射并减轻疼痛。利用SCS可显著减少甚或消除对镇痛药物的依赖。 FDA批准神经调节用于背痛和腿痛治疗已超过30年,但该装置的不同之处在于其体积微小并可通过标准穿刺针置入,同时其无线装置无需通过导线与电源

FDA批准用于缓解慢性背痛和腿痛的可注射微芯片神经调节装置(SCS系统)上市。


SCS系统为微小的可注射微芯片装置,并可向神经周围的电极发送微能量脉冲,从而触发反应使大脑对特定疼痛信号从重新映射并减轻疼痛。利用SCS可显著减少甚或消除对镇痛药物的依赖。

FDA批准神经调节用于背痛和腿痛治疗已超过30年,但该装置的不同之处在于其体积微小并可通过标准穿刺针置入,同时其无线装置无需通过导线与电源连接。该装置不含内部电池和其他有毒物质,并且不妨碍患者接受全身MRI检查。该装置预期将在2015年1月于美国上市。

原始出处:

FDA Okays Injectable Stimulation Device for Back, Leg Pain.FDA Approvals > Medscape Medical News.December 03, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=32834, encodeId=397532834ad, content=美厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jul 15 17:40:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839333, encodeId=6807183933359, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jan 05 16:09:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260016, encodeId=f9a01260016cd, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458905, encodeId=7536145890543, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2015-07-15 1dd82894m82(暂无匿称)

    美厉害

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=32834, encodeId=397532834ad, content=美厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jul 15 17:40:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839333, encodeId=6807183933359, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jan 05 16:09:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260016, encodeId=f9a01260016cd, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458905, encodeId=7536145890543, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2015-01-05 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=32834, encodeId=397532834ad, content=美厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jul 15 17:40:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839333, encodeId=6807183933359, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jan 05 16:09:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260016, encodeId=f9a01260016cd, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458905, encodeId=7536145890543, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=32834, encodeId=397532834ad, content=美厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Wed Jul 15 17:40:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839333, encodeId=6807183933359, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jan 05 16:09:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260016, encodeId=f9a01260016cd, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458905, encodeId=7536145890543, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Thu Dec 11 00:09:00 CST 2014, time=2014-12-11, status=1, ipAttribution=)]
    2014-12-11 lixiaol

相关资讯

汤森路透:药业新闻大事件 — 美国大选后FDA将面临重大变革?

  汤森路透走访多位相关人士后做出相关报道: 随着国会权利在两党间的交替以及21th Century Cures Initiative的巨大推动力,势必使FDA在2015年作出重大变革。 关于Cures改革的讨论草案,预计会在一月份推出,很可能会改变药物和设备开发流程,这会导致综合立法在今年晚些时候通过,Latham & Watkins’医疗保健和生命科学实践的合作

FDA不断推出监管新措施 释放了哪些信号?

随着2010版GMP的实施,对中国制药企业,尤其是对中小型制药企业,产生了很大的影响。那些规模小、产品结构简单或者老旧,盈利能力弱小、综合管理能力不足的企业,必须主动或者被动面对兼并和收购的浪潮。 CFDA不断推出监管新措施的5大信号 在过去的三年内,是中国制药深刻变更的前奏阶段;在未来几年,这种变革节奏还会进行。尽管CFDA彻底变更的框架还没有完全展示出来,但是随着过去1年中不断推出

FDA:药企飞行检查进入常态化

  近日,知名药企修正药业因飞行检查不合格被收回GMP证书,在行业引起极大关注。近日,安徽省食药监官网刊登消息,称又收回3家企业的药企的GMP证书。这意味着飞行检查将成为常态化、常规化的监督措施,力度和密度都将超过以往。药企尤其是中药企业要小心了。 据药圈的论坛消息,国家食药监总局日前下发通知,要求各省市食药监局在2014年10月至12月底,在全国范围内开展针对中药生产中提取和提

肿瘤Car-T免疫细胞治疗JCAR015获FDA突破性疗法认定

嵌合抗原受体-T细胞(CAR-T)疗法代表着当今最先进的肿瘤免疫细胞治疗技术,在相关临床试验中取得了巨大的成功,该领域已成为药品研发最热门的领域之一,也是投资合作的大热点。 目前,在CAR-T免疫疗法领域,诺华(Novartis)处于领先地位,其临床试验中有用于白血病、淋巴瘤、间皮瘤和胰腺癌的实验性产品。今年7月,FDA已授予诺华CAR-T免疫疗法CTL019突破性疗法认定。截至目前,诺华凭借出

美国药就不贵吗?

你的印象里是不是,新的专利药价格通常比较昂贵,没有专利的仿制药则便宜很多。错了,新英格兰杂志13日发表的一篇文章显示,美国卫生保健正见证着一个鲜为人知,但却越来越多的现象:部分仿制药,现在也极其昂贵! 阿苯达唑,是一个广谱抗寄生虫药物。阿苯达唑的首次推出是1982年,在位于美国之外的葛兰素史克(GSK)的前身公司,而食品和药物管理局(FDA)的批准上市是在14年后的1996。

阿特维斯新型抗生素ceftazidime-avibactam有望获FDA批准

阿特维斯近日宣布,FDA专家组建议批准该公司的新型抗生素,可以治疗由耐药菌引起的两种感染性疾病。 该抗生素名为ceftazidime-avibactam,抗感染药物咨询委员会于周五宣称,在无其他替代疗法的情况下,该药物治疗腹腔感染和尿路感染非常安全有效。然而,委员会同时也表示,有肾损伤的患者不宜使用。 抗感染药物咨询委员会还认为,在证据不足的情况下,不建议使用该抗生素治疗院内细菌性肺炎和菌